FLUTIFORM

This brand name is authorized in Austria, Australia, Cyprus, Germany, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Nigeria, Netherlands, Poland, Romania, Singapore, United Kingdom

Active ingredients

The drug FLUTIFORM contains a combination of these active pharmaceutical ingredients (APIs):

1 Fluticasone propionate UNII O2GMZ0LF5W - FLUTICASONE PROPIONATE

Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Read about Fluticasone

2 Formoterol fumarate dihydrate UNII W34SHF8J2K - FORMOTEROL FUMARATE

Formoterol is a predominantly selective β2-stimulator. Formoterol has bronchodilator activity in patients with reversible obstructive airway diseases. In humans formoterol is effective in the prophylaxis of bronchospasm induced by methacholine challenge. Read about Eformoterol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FLUTIFORM Pressurised inhalation, suspension	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03AK11		R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AK Adrenergics and other drugs for obstructive airway diseases
Discover more medicines within R03AK11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10007Q, 10008R, 2827T
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 09101458, 09101464, 09101470, 09101487, 09101493, 09101501
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 78536, 78537, 78538
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 135969, 149798, 173460
Country: FR	Base de données publique des médicaments	Identifier(s): 61046628, 64789302
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 210195, 210198, 210207, 356509, 373918, 374488, 376652, 376654, 381346, 381348, 381350, 381352, 381354, 390895
Country: HK	Department of Health Drug Office	Identifier(s): 62090, 62091, 62092
Country: IE	Health Products Regulatory Authority	Identifier(s): 33301, 33302, 33303, 33305
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7386, 7387, 7388
Country: JP	医薬品医療機器総合機構	Identifier(s): 2290802G1023, 2290802G2020, 2290802G3026, 2290802G4022
Country: NG	Registered Drug Product Database	Identifier(s): B4-8373
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 102547, 102555, 102563
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100289664, 100289670, 100289687
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W59644001, W59644002, W59645001, W59645002, W59646001, W59646002
Country: SG	Health Sciences Authority	Identifier(s): 14549P, 14550P, 14551P